Related Experiment Video
Updated: Mar 9, 2026
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
18.8K
Dendritic cell-based immunotherapy
Rachel L Sabado1, Sreekumar Balan1, Nina Bhardwaj1
1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA.
Cell Research
|December 28, 2016
Summary
Dendritic cell (DC) vaccines show promise for cancer immunotherapy but manufacturing methods lack standardization. Further research into human DC biology is needed to improve anti-tumor immunity and clinical outcomes.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Dendritic cell (DC)-based vaccination is an approved immunotherapy for metastatic hormone-refractory cancer.
- DC vaccines harness the patient's immune system to eliminate tumor cells.
- Clinical studies demonstrate DC vaccines are immunogenic and can correlate with clinical outcomes.
Purpose of the Study:
- To review current understanding of human DC biology derived from clinical studies.
- To identify areas for improvement in DC vaccine manufacturing and application.
- To enhance anti-tumor immunity through optimized DC-based vaccination strategies.
Main Methods:
- Review of clinical studies involving dendritic cell vaccines.
- Analysis of human dendritic cell biology in the context of cancer immunotherapy.
- Evaluation of current clinical approaches for DC vaccine manufacturing and administration.
Main Results:
- Despite proven immunogenicity, a consensus on DC vaccine manufacturing remains elusive.
- Clinical studies provide valuable insights into human DC biology and vaccine efficacy.
- Existing approaches to DC vaccination require refinement to maximize anti-tumor responses.
Conclusions:
- Standardized manufacturing protocols are critical for consistent DC vaccine efficacy.
- Further understanding of DC biology is essential for optimizing immunotherapy.
- Improving DC vaccine strategies holds potential for enhanced cancer treatment outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:30Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
01:27Cytotoxic T Cells-mediated Immune Response
7.8K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.8K